Rapid Point-of-Care Testing for Sickle Cell Anemia Market Size, Share & Trends Analysis Report By Type (Lateral Flow Immunoassay, Paper-based Rapid Diagnostics), By Technology, By Age Group, By Distribution Channel, By End Use, By Region, And Segment Forecasts,
Published Date: May - 2025 | Publisher: MIR | No of Pages: 240 | Industry: healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2999 Download Sample Ask for Discount Request CustomizationMarket Size & Trends
The size of the global rapid point-of-care testing for sickle cell anemia market in 2024 was valued at USD 304.83 million and will grow at a CAGR of 9.7% during the period between 2025 and 2035. The demand is fueled by the improvement in diagnostic technology and the increase in the need for affordable healthcare solutions. POC tests offer quicker, more precise, affordable diagnosis, particularly in low-resource settings where Sickle Cell Disease (SCD) has a high prevalence. Such breakthroughs facilitate early detection, which enhances patient outcomes. Moreover, increased investments, collaborations with global health institutions, and increasing healthcare infrastructure in emerging economies are propelling market expansion and widespread acceptance. According to an August 2023 report by ScienceDirect, between 2000 and 2021, the national incidence rate of SCD remained stable, but the total number of babies born with the condition globally increased by 13.7%, reaching 515,000 births, primarily driven by population growth in the Caribbean and western and central sub-Saharan Africa. Sickle Cell Disease (SCD) is an inherited disorder of the blood that leads to the formation of abnormally shaped red blood cells.
The sickle-shaped cells can lead to excruciating pain, anemia, and possible organ damage because they have a tendency to obstruct blood flow. India has one of the highest reported frequencies of the sickle β-globin allele, as reported by the Journal of Hematology and Allied Science (JHAS). It is the second most impacted nation as far as sickle β-globin thalassemia is concerned. The World Health Organization (WHO) approximates that 4.5% to 5% of the world's population are carriers of hemoglobinopathy traits. In India alone, there are about 30 million carriers, with an average national prevalence of 3.3%. Sickle cell anemia in India has a wide variation in incidence, ranging from 1% to 44% across various regions. Birth prevalence of SCD, which estimates the incidence of affected infants (≤1-year-old) via newborn screening programs, is most prominent in sub-Saharan Africa (500-2000 per 100,000 population), followed by South American and Caribbean Islands (20-1000 per 100,000).
By comparison, the birth prevalence in the United States and European nations is lower at ≤500 per 100,000. Global SCD hotspots are India, the Middle East, North-East Africa, and sub-Saharan Africa, with mortality rates being disproportionately high in low-resource areas like India and Africa. In June 2023, a report by the Institute for Health Metrics and Evaluation (IHME) brought to light that between 2000 and 2021, although the national incidence rates of SCD were quite stable, the overall births of babies with SCD rose by 13.7% worldwide. Early and accurate identification of SCD are critical for efficient disease control and management. Traditional methods of diagnosis usually demand well-stocked laboratories and specialized medical centers, which are hard to find in the resource-poor setting. This need has pushed the implementation of rapid point-of-care (POC) diagnostic technologies, which provide a fast and convenient option for the diagnosis of SCD.
The fast-growing point-of-care (POC) testing market for sickle cell anemia (SCA) has been expanding steadily in recent years due to advances in diagnostic technologies.
These have led to quicker, better, and less expensive testing products, facilitating earlier diagnosis and treatment of sickle cell disease (SCD) in an easier-to-reach manner, especially in resource-constrained environments. In contrast to conventional techniques, new POC instruments are made to be small, easy to use, and deliver quick results, generally between 15 to 30 minutes, making them well suited for application in remote and underserved communities with a high rate of SCD. For instance, Sickle SCAN-EZ is a multiplexed, qualitative point-of-care immunoassay for the quick diagnosis of sickle cell disease. It can also screen for sickle cell trait, sickle cell anemia, and HbSC disease, taking only the time span of 5 minutes.
Report Coverage & Deliverables
PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Market Concentration & Characteristics
The rapid point-of-care testing for sickle cell anemia market demonstrates a high degree of innovation. Recent advancements in lateral flow immunoassays (LFIA) have further enhanced SCD diagnosis, particularly in low-resource areas. One notable innovation is the multiplexed, allele-specific recombinase polymerase amplification (RPA) assay, which uses a lateral flow readout. This technology detects multiple mutations in the β-globin gene, the primary cause of SCD, providing a highly efficient and accurate method for rapid diagnosis.
Moreover, optical nanoparticles integrated into LFIA platforms have significantly improved the sensitivity and specificity of these tests, positioning them as powerful tools for diagnosing various diseases, including SCD. Another example of innovative progress is the E-junction lateral flow immunoassay, specifically designed for large-scale SCD screening in low- and middle-income countries (LMICs). This low-cost, user-friendly POC device can diagnose healthy individuals, SCD patients, and carriers from just a single drop of whole blood. Its affordability and reliability make it ideal for regions with limited access to traditional diagnostic methods, effectively addressing the high mortality rates associated with delayed diagnosis.
The rapid point-of-care testing for sickle cell anemia market experiences a high level of mergers and acquisitions (M&A), as major players seek to broaden their technological capabilities, enhance their product portfolios, and enter new regional markets. Several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies. Key players engaged in this growth strategy include Sysmex Corporation and others.
The rapid point-of-care testing for sickle cell anemia industry is regulated and driven by government support. Alongside governmental efforts, non-governmental organizations (NGOs) play a crucial role in expanding the reach and effectiveness of early screening initiatives. NGOs, including both international health organizations and local community groups, frequently partner with government agencies to fund and implement screening programs. These organizations contribute essential resources such as healthcare worker training, technical support for POC device usage, and logistical assistance to reach remote areas. Companies operating in the region are receiving government support. For instance, in 2023, BioMedomics Inc. received a USD 222,958 grant from the U.S. Department of Health and Human Services to develop low-cost, rapid tests for the quantitative measurement of HbF and HbS in sickle cell disease patients. Utilizing a lateral flow immunoassay platform, the test aims to provide near-patient measurements within minutes, facilitating immediate clinical decisions at the point of patient treatment.
Product expansion in the rapid point-of-care testing for sickle cell anemia market is at a high level. For instance, in June 2024, BioMedomics announced the launch of a three-year grant program aimed at enhancing the testing and management of Sickle Cell Disease (SCD) in Sub-Saharan African countries. Commencing on June 19, 2024, coinciding with World Sickle Cell Disease Day, this initiative reflects BioMedomics' commitment to improving global health through innovative diagnostics and education. The program seeks to raise SCD awareness and facilitate the availability and affordability of point-of-care testing in the region, with BioMedomics collaborating with local distributors for implementation.
The market for rapid point-of-care testing for sickle cell anemia is witnessing a medium to high level of regional expansion as companies aim to tap into growth opportunities in emerging markets while solidifying their presence in established regions. Asia-Pacific, Latin America, and the Middle East are becoming key targets due to rising healthcare investments, increasing awareness of diagnostic testing, and expanding healthcare infrastructures. Market leaders are setting up local manufacturing units, establishing partnerships with regional distributors, and customizing product offerings to meet specific market requirements. However, regional expansion efforts are often challenged by varying regulatory landscapes and market access barriers, requiring tailored strategies for each geography.
Type Insights
Lateral flow immunoassay held the largest revenue share of 51.66% in 2024. The lateral flow assays (LFA) segment is witnessing rapid market growth in the field of point-of-care (POC) testing for sickle cell anemia (SCA), driven by a combination of product innovation, affordability, technological advancements, and increasing demand for decentralized diagnostic solutions. As global awareness of sickle cell disease (SCD) and sickle cell trait (SCT) grows, particularly in high-prevalence regions like sub-Saharan Africa, India, and the Middle East, there is a rising need for fast, reliable, and accessible screening tools that can be deployed at the grassroots level.
A key factor in the growth of this market is the launch of next-generation LFA products that improve upon earlier diagnostic methods. For instance, in December 2024, BioMedomics introduced Sickle SCAN EZ, a major advancement built on the success of the original Sickle SCAN, the world’s first Point-of-Care Test (POCT) for SCD and SCT. The new Sickle SCAN EZ is designed with a bulk strip configuration specifically optimized for high-volume screening, maintaining the same robust technology but tailored for mass public health initiatives, school screenings, and antenatal clinics. This product is expected to significantly accelerate screening programs by reducing costs and simplifying logistics.
The paper-based rapid diagnostics segment is expected to grow at the fastest CAGR over the forecast period. The paper-based tests market in rapid point-of-care (POC) testing for sickle cell anemia (SCA) is steadily expanding, driven by the growing demand for low-cost, easy-to-use diagnostic solutions in underserved and remote regions. These tests offer an affordable and accessible alternative to conventional laboratory methods, enabling early detection and timely intervention, critical for managing sickle cell disease effectively. Unlike lateral flow assays, paper-based tests such as HemoTypeSC utilize vertical flow technology to detect hemoglobin variants (HbA, HbS, and HbC) from a small blood sample. They require no electricity, refrigeration, or specialized training, making them ideal for deployment in resource-limited healthcare systems across sub-Saharan Africa, South Asia, and other high-prevalence regions. Priced at less than USD 2 per test, HemoTypeSC is widely recognized for its accuracy and utility in field-based screening programs.
Technology Insights
Hemoglobin electrophoresis accounted for the largest revenue share of the rapid point-of-care testing for sickle cell anemia industry in 2024. The hemoglobin electrophoresis segment is experiencing notable growth within the rapid point-of-care testing (POCT) market for sickle cell anemia. This expansion is driven by technological advancements that have transformed traditional electrophoresis into portable, efficient, and user-friendly formats suitable for diverse healthcare settings. Another prominent innovation is the Gazelle Hb Variant Test, which has gained attention for its diagnostic precision and practical utility. In October 2024, findings presented at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassemia (ASCAT) highlighted the test’s effectiveness in both newborn and premarital screenings. In Ghana, it enabled cost-effective, rapid identification of common hemoglobin variants directly at the point of care.
PCR is expected to grow at a substantial CAGR over the forecast period. Polymerase Chain Reaction (PCR) technology has significantly enhanced the diagnostic landscape for Sickle Cell Anemia (SCA) by enabling precise identification of mutations in the β-globin gene responsible for the disease. PCR's ability to amplify specific DNA sequences facilitates accurate differentiation between various forms of Sickle Cell Disease (SCD), which is essential for effective patient management.
Age Group Insights
Newborn screening (12 months and below) segment dominated the rapid point-of-care testing for sickle cell anemia market in 2024, supported by The Newborn Screening (12 months and below) segment is experiencing significant growth within the Rapid Point-of-Care Testing (POCT) market for Sickle Cell Anemia (SCA). This expansion is driven by the high incidence of SCA among newborns, the implementation of newborn screening programs, and advancements in POCT technologies. According to a March 2024 report by the Centers for Disease Control and Prevention (CDC), approximately one in every 365 Black or African American newborns in the United States is born with sickle cell disease (SCD), a condition associated with complex health needs. This high prevalence underscores the critical need for early detection and intervention to improve health outcomes.
The other age groups (1 to 25 & above 60 years) segment is anticipated to grow at a substantial CAGR over the forecast period. The Adult Screening (25 to 60 years) segment is witnessing notable growth in the Rapid Point-of-Care Testing (POCT) market for Sickle Cell Anemia (SCA). This expansion is driven by increased awareness, advancements in testing technologies, and collaborative efforts to enhance understanding of the disease. A primary tool in adult screening is the Sickle Cell Solubility Test (SCST), which detects the presence of hemoglobin S (HbS) in blood samples. The SCST is valued for its affordability, rapid results, and high sensitivity and specificity. However, it cannot quantify HbS levels and requires confirmatory tests to differentiate between sickle cell trait and sickle cell disease. Despite these limitations, the SCST remains a standard screening method in various settings, including the U.S. military and the National Collegiate Athletic Association.
Sector Type Insights
The government labs segment dominated the rapid point-of-care testing for sickle cell anemia market in 2024. Government laboratories are playing a crucial role in expanding access to rapid point-of-care (POC) testing for sickle cell anemia, particularly in low- and middle-income countries (LMICs). Governments in Africa, such as Nigeria and Ghana, keep introducing national programs to introduce cost-effective and decentralized testing methods to combat high sickle cell prevalence. For instance, Nigeria's Ministry of Health partnered with global organizations to roll out the HemoTypeSC test kits in rural areas, enabling early detection. In the U.S., federal and state-funded health labs are increasingly investing in rapid diagnostics, spurred by newborn screening mandates and funding from the Centers for Disease Control and Prevention (CDC). These efforts aim to reduce diagnostic delays and improve early intervention.
The private labs segment is anticipated to grow at the fastest CAGR over the forecast period. Private laboratories significantly contribute to the market by offering advanced diagnostic services and fostering innovation in point-of-care (POC) testing technologies. For instance, in June 2023, Mylab Discovery Solutions introduced the PathoCatch Sickle Cell Rapid Test, an indigenous strip-based point-of-care diagnostic tool for sickle cell anemia. This test delivers results within minutes, enabling healthcare professionals to diagnose and manage the disease promptly. Approved by the Central Drugs Standard Control Organization (CDSCO), the test aligns with the Indian government's objective to eliminate sickle cell anemia by 2047. The agility of private entities enables swift adaptation to emerging healthcare needs, thereby improving patient outcomes.
Distribution Channel Insights
The B2B (Business-to-Business) segment dominated the rapid point-of-care testing for sickle cell anemia industry in 2024. The B2B channel is the dominant distribution model for rapid point-of-care tests for sickle cell anemia, primarily involving sales to hospitals, diagnostic labs, governments, and NGOs. Manufacturers such as BioMedomics, PerkinElmer, and DIAsource are securing large procurement contracts with ministries of health and international organizations like UNICEF and WHO. These bulk purchases are often tied to national screening initiatives, especially in Sub-Saharan Africa and Southeast Asia. In 2023, UNICEF awarded a major tender for rapid test kits to expand sickle cell testing in over 10 African countries.
The B2C (Business-to-Consumer) segment is anticipated to grow at the fastest CAGR over the forecast period. The B2C market for sickle cell rapid testing is still in its early stages but growing steadily, especially in North America and parts of Europe. Consumers are becoming more proactive about genetic and chronic disease screening, driving interest in direct-to-consumer (DTC) health solutions. Startups and e-commerce platforms now offer at-home genetic screening kits that include hemoglobin variants as part of broader health panels.
End Use Insights
The hospitals & clinics segment accounted for the largest revenue share of the rapid point-of-care testing for sickle cell anemia market in 2024. Hospitals and clinics are primary end users of rapid POC tests for sickle cell anemia. The integration of such tests into routine practice enhances patient care by reducing diagnostic delays and enabling prompt management of the disease. In emergency settings, rapid POC tests are invaluable for quickly assessing patients presenting with symptoms suggestive of sickle cell crises. This capability allows healthcare providers to make informed decisions swiftly, improving patient outcomes and optimizing resource utilization within the hospital or clinic.
The homecare settings segment is expected to grow at the fastest CAGR during the forecast period. Home-based testing for sickle cell anemia is emerging as a niche but growing segment, especially in high-income countries. The increasing prevalence of disease has accelerated interest in at-home diagnostics, and now similar models are being explored for chronic conditions like sickle cell disease. Companies are working on expanding their test menus to include hemoglobinopathy panels for home collection. The launch of point-of-care (POC) sickle cell testing in homecare settings, like Sickle SCAN EZ, offers rapid, reliable diagnostics, empowering clinicians and facilitating early diagnosis and management of sickle cell disease (SCD) and sickle cell trait (SCT).
Regional Insights
North America dominated the rapid point-of-care testing for sickle cell anemia market and accounted for a 43.97% share in 2024. Owing to the growing prevalence of blood illnesses amongst the population, and is a rising demand for hematology diagnostic test kits and equipment. For instance, the American Society of Hematology highlighted that Sickle cell trait, a blood disorder, affects 1 million to 3 million Americans, and more than 100 million people worldwide carry the sickle cell trait. The presence of several pharmaceutical and medical device companies is also expected to boost the demand for the hematology diagnostics market. One study in the US found that despite universal newborn screening, only 31% of SCD cases receive long-term follow-up after diagnosis.
U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Trends
The U.S. leads the rapid point-of-care testing for sickle cell anemia industry, driven by the rising awareness, increasing prevalence of the disorder, particularly among the African American population, and the growing emphasis on early diagnosis and intervention. Rapid POC diagnostics offer significant advantages, including quick turnaround times, ease of use in diverse healthcare settings, and reduced reliance on laboratory infrastructure, which makes them especially valuable in both rural and urban community clinics. The cost-effectiveness of these tests further supports their adoption, particularly in initiatives aimed at expanding newborn screening and school-based health programs. Moreover, public-private partnerships, funding support, and innovations from companies like BioMedomics and Silver Lake Research are driving market penetration. As healthcare systems increasingly prioritize personalized and preventative care, the demand for efficient and scalable POC solutions is expected to continue rising, creating robust growth opportunities in the forecast period.
Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market Trends
The Europe rapid point-of-care testing for sickle cell anemia industry is rapidly evolving. As healthcare systems in countries such as France, Italy, and the UK expand their screening programs, the availability of such portable and efficient diagnostics is improving access and uptake, particularly in underserved communities and rural areas. This aligns with Europe's broader commitment to preventive care and rare disease management, thereby strengthening the market potential for rapid POC tests for sickle cell anemia.
The UK rapid point-of-care testing for sickle cell anemia market is experiencing significant growth. NHS data indicates that there were slightly more than 32,000 hospital admissions in England related to sickle cell disorders between 2023 to 2024. Of these, nearly 14,000 admissions were specifically due to sickle cell anemia crises. The NHS's commitment to innovative testing underscores the importance of efficient diagnostic tools in managing SCD. Further, in May 2023, NHS England, in collaboration with NHS Blood and Transplant, launched a genetic testing initiative for individuals with sickle cell disease and related conditions. This partnership also offers genetic counseling services to patients and their families, supporting them in understanding test results and making informed decisions regarding their treatment and care options.
The rapid point-of-care testing for sickle cell anemia market in Germany is growing. In 2023, according to PfizerPro, an estimated 3,200 people in Germany lived with sickle cell disease (SCD), with a birth prevalence of roughly 1 in 2,500 newborns. Healthcare providers have observed a growing need for effective diagnostic solutions. Rapid point-of-care testing can significantly aid in early detection, particularly in urban centers with diverse populations.
Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market Trends
Asia Pacific rapid point-of-care testing for sickle cell anemia industry is anticipated to witness significant growth over the forecast period. The region is emerging as a promising frontier for rapid point-of-care (POC) testing for sickle cell anemia, driven by increasing awareness, advancements in healthcare infrastructure, and rising demand for accessible diagnostics in rural and underserved areas. Countries such as India, Thailand, and parts of Southeast Asia are witnessing a growing prevalence of hemoglobinopathies like sickle cell anemia and beta thalassemia, particularly among tribal and ethnic minority populations.
China rapid point-of-care testing for sickle cell anemia market held a substantial revenue share in 2023. In China, SCD is extremely rare due to the low prevalence of the responsible genetic mutations within the indigenous population. Consequently, there is minimal demand for rapid POC testing for SCD. However, with increasing globalization and potential migration from regions where SCD is more common, healthcare providers should remain vigilant. Implementing targeted screening programs for at-risk individuals, particularly those of African or Mediterranean descent residing in China, could be beneficial.
The rapid point-of-care testing for sickle cell anemia market in Japan is progressing steadily. Japan's market for rapid point-of-care testing for sickle cell anemia remains niche due to the low domestic prevalence of the disease. However, multinational companies such as Siemens Healthineers, Roche Diagnostics, and Sysmex, Japan’s leading diagnostics company, are focusing on developing advanced diagnostic tools, including molecular-level POC tests. The level of market competition is low to moderate but driven by high innovation standards, regulatory rigor, and a strong demand for high-quality diagnostics in clinical and academic settings.
Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market Trends
The Latin American rapid point-of-care (POC) testing for sickle cell anemia industry is witnessing increasing attention due to the region's growing focus on genetic blood disorders and improved diagnostic infrastructure.
The Brazil rapid point-of-care testing for sickle cell anemia market is witnessing substantial growth. Brazil has one of the highest incidences of sickle cell disease (SCD) outside Africa, particularly among Afro-Brazilian populations. According to Brazil’s Ministry of Health, in Brazil, sickle cell disease (SCD) is a significant public health issue, with an estimated 60,000 to 100,000 individuals affected, and about 4% of the population carrying the sickle cell trait. The incidence is around 45.92 cases per 100,000 live births.
Middle East & Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market Trends
The Middle East and Africa (MEA) rapid point-of-care testing for sickle cell anemia industry is poised for growth. Sickle cell anemia is a major public health concern across several Middle Eastern and African countries, especially due to genetic predisposition in specific populations and consanguineous marriages in certain regions. The World Health Organization (WHO) identifies Sub-Saharan Africa as bearing over 75% of the global sickle cell burden. At the same time, Saudi Arabia, Kuwait, and the UAE have recognized regional clusters of the disease primarily in Eastern Provinces and among certain tribal communities.
The Saudi Arabia rapid point-of-care testing for sickle cell anemia market is experiencing robust growth. Saudi Arabia has implemented a national premarital screening program targeting genetic diseases, including SCD and thalassemia. This creates a solid foundation for market demand in early-stage and rapid diagnostics. The country is open to advanced healthcare technologies, including AI-driven diagnostics. Major players such as Siemens Healthineers, Abbott, and Bio-Rad are active, and the market favors innovative and certified technologies. There's ample opportunity for strategic partnerships with hospitals and government health programs.
Key Rapid Point-of-Care Testing for Sickle Cell Anemia Company Insights
Some of the key players operating in the rapid point-of-care testing for sickle cell anemia market include BioMedomics Inc.; Silver Lake Research Corporation; Bio-Rad Laboratories, Inc.; Trivitron Healthcare; Hemex Health; Sysmex Corporation; EKF Diagnostics Holdings plc; and HemoCue America (Danaher Corporation). These established companies are driving innovation through robust R&D capabilities, portable diagnostic platforms, and user-friendly rapid test kits that enable early and accurate detection of sickle cell disease. Their strategies are centered around continuous product development, geographic expansion, and strategic collaborations with healthcare providers and public health programs to improve accessibility in high-prevalence regions.
Companies like BioMedomics and Silver Lake Research are leading the way with highly sensitive and specific tests, such as Sickle SCAN and HemoTypeSC, respectively, while others are leveraging global distribution networks to reach underserved populations. The market is poised for growth as these players work to enhance diagnostic capabilities, reduce turnaround times, and support early intervention efforts for sickle cell disease.
Key Rapid Point-of-Care Testing for Sickle Cell Anemia Companies
The following are the leading companies in the rapid point-of-care testing for sickle cell anemia market. These companies collectively hold the largest market share and dictate industry trends
- BIOMEDOMICS INC.
- Silver Lake Research Corporation
- Bio-Rad Laboratories, Inc.
- Trivitron Healthcare
- Hemex Health
- Sysmex Corporation
- EKF Diagnostics Holdings plc.
- HemoCue America (Danaher)
Recent Developments
-
In December 2024, BioMedomics Inc. developed the Sickle SCAN test, a rapid, point-of-care diagnostic tool for sickle cell disorders. This immunoassay detects hemoglobins A, S, and C using a small blood sample, providing results in under five minutes without the need for electricity or advanced equipment. Clinical studies have demonstrated its high sensitivity and specificity, making it suitable for newborn screening and genetic counseling. The test has received CE Mark approval, indicating compliance with European health, safety, and environmental standards.
-
In November 2024, Hemex Health unveiled new product offerings for its Gazelle Diagnostic Device. The next-generation Snap Cartridge simplifies sample preparation, enabling minimally trained health workers to perform tests for hemoglobin variants, including sickle cell disease and beta-thalassemia. Additionally, the Gazelle Ferritin FIA Test offers accurate measurement of ferritin levels for improved diagnosis of iron deficiency anemia.
-
In May 2023, Molbio Diagnostics collaborated with ShanMukha Innovations to introduce SickleCert, India's first CDSCO-approved point-of-care test for sickle cell anemia. Developed with High-Performance Optical Spectroscopy (HPOS) technology from the Indian Institute of Science (IISc), SickleCert delivers accurate results within 15 minutes using a small blood sample. The system includes a portable analyzer, HaemoCube, and a smartphone app for data recording and integration with health records.
Rapid Point-of-Care Testing for Sickle Cell Anemia Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 328.69 million |
|
Revenue forecast in 2030 |
USD 522.83 million |
|
Growth rate |
CAGR of 9.7% from 2025 to 2035 |
|
Actual data |
2018 - 2023 |
|
Forecast period |
2025 - 2035 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2035 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Type, technology, age group, sector type, end use, distribution channel, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Spain; Italy; Sweden; Denmark; Sweden; Norway; Japan; China; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
Biomedomics Inc.; Silver Lake Research Corporation; Bio-Rad Laboratories, Inc.; Trivitron Healthcare; Hemex Health; Sysmex Corporation; EKF Diagnostics Holdings plc; HemoCue America (Danaher) |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market Report Segmentation
Type Outlook (Revenue, USD Million, 2018 - 2035)
-
-
Lateral Flow Immunoassay
-
Paper-Based Rapid Diagnostics
-
Others
-
-
Technology Outlook (Revenue, USD Million, 2018 - 2035)
-
Hemoglobin Electrophoresis
-
Polymerase Chain Reaction (PCR)
-
Isothermal Amplification Assays
-
Others
-
-
Age Group Outlook (Revenue, USD Million, 2018 - 2035)
-
Newborn Screening (12 months and below)
-
Adult Screening (25 to 60 years)
-
Other Age Groups (1 to 25 & Above 60 years)
-
-
Sector Type Outlook (Revenue, USD Million, 2018 - 2035)
-
Government Labs
-
Private Labs
-
Corporate Labs
-
PPP (Public-Private-Partnerships)
-
-
End Use Outlook (Revenue, USD Million, 2018 - 2035)
-
Hospitals & Clinics
-
Diagnostics Laboratories
-
Research Institutions
-
Homecare Settings
-
Others
-
-
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2035)
-
B2B (Business-to-Business)
-
B2C (Business-to-Consumer)
-
-
Regional Outlook (Revenue, USD Million, 2018 - 2035)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Spain
-
Italy
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa (MEA)
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy